HEMO — Hemogenyx Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- £8.15m
- £10.57m
Annual income statement for Hemogenyx Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 2.15 | 2.7 | 4 | 6.47 | 5.38 |
| Operating Profit | -2.15 | -2.7 | -4 | -6.47 | -5.38 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.1 | -5.11 | -3.99 | -6.7 | -5.63 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.1 | -5.11 | -3.99 | -6.7 | -5.63 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.08 | -5.1 | -3.98 | -6.69 | -5.62 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.08 | -5.1 | -3.98 | -6.69 | -5.62 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.01 | -2.64 | -1.62 | -2.37 | -1.7 |